drugset / Trial / NCT05690984
Elimination of Minimal Residual Disease After Transplant
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.
Timeline
- Start
- 2023-06-26
- Primary completion
- 2026-09
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 4 mg | Intravenous |
| Subject | Isatuximab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |